C Diff Drug Development

Adverse event rates did not significantly differ between patients treated with both DAV132 and Fluoroquinolone and patients treated only with fluoroquinolone.

There is an urgent global need for new strategies and drugs to control and treat multi-drug resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline. …

SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop

Clostridioides difficile infection (CDI) is a common cause of nosocomial diarrhea. TcdB is a major C. difficile exotoxin that activates macrophages to promote inflammation and epithelial damage. Lysosome impairment is a known trigger for inflammation. Herein, we hypothesize that TcdB c …

The panel reviews phase 3 data behind SER-109, another novel FMT therapy for patients with recurrent Clostridioides difficile infection.

Summit Therapeutics Inc. announced topline results for the Phase III Ri-CoDIFy study evaluating its investigational drug, ridinilazole, for the treatment of and Sustained Clinical Response for... | January 6, 2022

Context Clostridioides difficile infection (CDI) is one of the most common infectious causes of hospital-acquired diarrhea. The actual burden of the disease is underestimated in India due to inadequate diagnostic methods and limited studies conducted. Aims The aim of this study …

The panel reviews phase 3 data behind SER-109, another novel FMT therapy for patients with recurrent Clostridioides difficile infection.

We applied a mathematical framework originally used to model the effects of multiple inhibitors on enzyme activity to guide the development a therapeutic antibody cocktail, LMN-201, to prevent and treat C. difficile infection (CDI). CDI causes hundreds of thousands of cases of severe, often recurrent diarrhea and colitis in the United States annually and is associated with significant morbidity and mortality worldwide. Current therapies for preventing recurrent CDI are only partially successful, and there are no options available to prevent initial bouts of CDI in at-risk populations. Almost all antibody therapies have been developed and administered as monotherapies. Antibody cocktails are relatively rare even though they have the potential to greatly increase efficacy. One reason for this is our limited understanding of how antibody interactions can enhance potency, which makes it difficult to identify and develop antibodies that can be assembled into optimally effective cocktails. In contrast to the view that antibody synergies depend on unusual instances of cooperativity or allostery, we show that synergistic efficacy requires nothing more than that the antibodies bind independently to distinct epitopes on a common target. Therefore, synergy may be achieved much more readily than is generally appreciated. Due to synergy the LMN-201 antibody cocktail, which targets the C. difficile exotoxin B (TcdB), is 300- to 3000-fold more potent at neutralizing the most clinically prevalent TcdB toxin types than bezlotoxumab, the only monoclonal antibody currently approved for treatment or prevention of CDI. The efficacy of LMN-201 is further enhanced by inclusion of a phage-derived endolysin that destroys the C. difficile bacterium, and which therefore has a complementary mechanism of action to the antibody cocktail. These observations may serve as a paradigm for the development of high potency biologic cocktails against targets that have proven challenging for single-agent therapies. ### Competing Interest Statement J. R. and B. F. are the founders and current employee of Lumen Bioscience, Inc. and each owns stock and stock options in Lumen. H. Z., M. T., M. D., M. G., A. M., K. K., A. P., B. J., N. K., M. Z., C. B., M. H., H. T., N. S., K. C., T. P., S. E., S. S., J. D., C. S., D. F., L. G., C. G., and C. B. are, or were, employees of Lumen; all current and former employees own stock or stock options in Lumen. Lumen has issued U.S. patents including U.S. patent nos. 10,131,870, 10,415,012, 10,336,982, 10,415,013, and pending U.S. patent applications including Nos. 16/570,520, 17/056,306, and 17/264,837 relating to its spirulina transformation, expression, delivery and protein engineering platform and certain research described in this article.

Clostridioides difficile (C. difficile) is a gram-positive, anaerobic spore-forming bacterium and a major cause of antibiotic-associated diarrhea. Humans are naturally resistant to C. difficile infection (CDI) owing to the protection provided by healthy gut microbiota. When the …

Clinical trial success for two proprietary bacteria mixtures

Ridinilazole was tested in a Phase 3 trial in the treatment of C. Difficile.

Clostridioides difficile is an enteric bacterium whose exotoxins, TcdA and TcdB, inactivate small GTPases within the host cells, leading to bloody diarrhea. In prior work, our group engineered a panel of potent TcdB-neutralizing designed ankyrin repeat proteins (DARPin) as oral therapeutics against …

The Asia-Pacific region has seen a 158% increase in the number of musculoskeletal disorders trials taking place over the past...Read More...

Shared insight on the phase 3 data behind RBX2660, a novel FMT therapy for patients with recurrent Clostridioides difficile infection.

The investigational therapy, ibezapolstat, demonstrated promising results in early trials.

Researchers at Albert Einstein College of Medicine, led by Vern Schramm, Ph.D., have developed a novel compound that targets C. difficile.

The intestinal pathogen Clostridioides (C.) difficile is a major cause of diarrhea both in hospitals and outpatient in industrialized countries. This bacterium produces two large exotoxins, toxin A (TcdA) and toxin B (TcdB), which are directly responsible for the onset of clinical symptoms of …

Proline racemases (PRAC), catalyzing the L-proline and D-proline interconversion, are essential factors in eucaryotic pathogenes such as Trypanosoma cruzi, Trypanosoma vivax and Clostridioides difficile. If the discovery of irreversible inhibitors of Trypanosoma cruzi PRAC (TcPRAC) led to innovative …

Scientists around the world have been working in earnest to improve understanding of an increasingly virulent superbug, Clostridium difficile. The highly contagious hospital-acquired pathogen, designated by the Centers for Disease Control and Prevention as one of the five most urgent threats to the U.S. healthcare system, causes more than 500,000 infections and 29,000 deaths each year at a total societal cost exceeding $5 billion.

Many of the measures put in place because of COVID-19 have also helped to reduce the rates of C difficile infections.

Vedanta revealed positive new data for its C. difficile microbiome therapeutic. But is it too late an entrant into the field?

Acurx Pharmaceuticals, Inc. announced today that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022.

The investigational therapy, ibezapolstat, demonstrated promising results in early trials.

Clostridioides difficile is one of the major causes of nosocomial infections worldwide. Antibiotic-associated diarrhea, pseudomembranous colitis, and toxic megacolon are the most common forms of C. difficile infection (CDI). Considering the high antibiotic resistance of C. difficile isolates and the …

Clostridioides difficile infection (CDI) is a leading cause of antibiotic-associated diarrhoea. Adhesion of this Gram-positive pathogen to the intestinal epithelium is a crucial step in CDI, with recurrence and relapse of disease dependent on epithelial interaction of its endospores. Close pr …

.@Summitplc’s #ridinilazole reduced recurrence of #Cdiff #infections but did not reach superiority to #vancomycin in Ph3 #ClinicalTrialsBelieve precision #antibiotic spares #microbiome from damagehttps://t.co/ED6zpkmEqQ#Cdifficile #InfectiousDiseases pic.twitter.com/oUc6TuNkn7— DDNews Online (@DDNewsOnline) December 20, 2021

Recursion Pharma (RXRX) is hoping to revolutionize drug discovery with its Recursion OS technology; potential to improve drug discovery and processing capabilities.